SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Ivonescimab Receives NMPA Priority Review

Akeso said China’s NMPA granted priority review to ivonescimab for first-line biliary tract cancer.

Related stories